Neutrophil-activating protein 1/interleukin 8 (NAP-1/IL-8)' was first identified as a 72 amino acid peptide secreted by monocytes in response to bacterial LPS, with the properties of activating and attracting polymorphonuclear leukocytes (PMN) in vitro (1). Subsequently several different types ofcells, including macrophages and endothelial cells, were found to synthesize NAP-1/IL-8 upon stimulation with TNF or IL-1. Sequence data indicate that NAP-1/IL-8 is homologous to a group of peptides including platelet basic protein, platelet factor 4, and macrophage inflammatory protein 2 . In vivo accumulation of PMN at sites of injection of NAP-1/IL-8 suggests that it may participate in the recruitment of PMN into inflamed tissue, and NAP-1/IL-8 has been identified in skin lesions of patients with psoriasis (1).
a generous gift of Dr. Liliana Ossowski (The Rockefeller University, New York, NY) . Fibronectin was obtained from the New York Blood Center (New York, NY) . fMLP, formylnorleucyl-leucyl-phenylalanine (fNLLP), PMA, phorbol dibutyrate (PDB), and aprotinin were purchased from Sigma Chemical Co ., St . Louis, MO . Pyrogen-free human serum albumin (HSA) was supplied by Armour Pharmaceutical, Kankakee, IL . Buffers used were : PBS (137 mM NaCl, 2 .7 mM KCI, 0 .9 mM CaC12, 0 .5 MM MgC1 2 , and 8 mM phosphate, pH 7 .4) ; PD (PBS without CaC12 or MgC12 but with 0 .02% NaN 3 ) ; and HAP (pyrogenfree PBS [Sigma] , 0 .05% glucose, 0 .5 mg/ml HSA and 0 .3 U/ml aprotinin) .
Antibodies . mAb provided by colleagues were : OKM10, directed against CD11b (6), from Dr. Gideon Goldstein (Ortho Pharmaceuticals, Rariton, NJ) ; LeuM5, directed against CDllc (10) , from Dr. Louis Lanier (Becton Dickinson & Co ., Mountain View, CA) ; 543, directed against CRl (11) , from Dr. Robert Schreiber (Washington University, St . Louis, MO); and T2G1, directed against fibrinogen (12) , from Dr. Bohdan Kudryk (New York Blood Center, New York, NY) . 3G8, directed against Fc y receptor III (FcyRIII, CD16) (13) ; W6/32, directed against HLA-A,B,C (14) ; and IB4, directed against CD18 (6), were as described .
Cell Preparation. Human PMN were isolated from freshly drawn, normal blood on FicollHypaque gradients (15) and suspended at a final concentration of 2 x 106 cells/ml in HAP buffer.
Cytoplasts were prepared from cytochalasin B-treated PMN exactly as described (16) , washed five times to remove the cytochalasin, and suspended to a concentration of 4 x 10 6 /ml in HAP buffer. Preparations of cytoplasts were previously characterized by enzyme assays and electron microscopy to be free of granular constituents (4) .
Flow Cytometry. Cells were exposed to mAb (5 1~g/ml in PD, 0 .1 01o HSA) for 15 min at 0°C, washed, and incubated with fluoresceinated affinity-purified goat anti-mouse IgG F(ab')2 (7 Itg/ml in PD, 0 .1% HSA) (Tago Inc., Burlingame, CA) for 45 min at 0°C . Fluorescence was measured on a Becton Dickinson FACScan cell analyzer. The mAb T2G1 (antifibrinogen) was used as a negative control in all experiments, and the mean fluorescence channel derived from this antibody, which was the same as that obtained by omitting the primary antibody, was subtracted from those of experimental samples .
Preparation of Opsonized Erythrocytes. Sheep erythrocytes (E) were coated with IgG or IgM as previously described (17) . Erythrocytes coated with C3bi (EC3bi) were prepared by incubating EIgM in C5-deficient human serum (Sigma Chemical Co.) as described (18) . Erythrocytes coated with the biosynthetic precursor of LPS, lipid IVa, were prepared as described (8) .
Assays for Attachment and Phagocytosis of Ligand-coated Erythrocytes. Assays for rosetting and phagocytosis by adherent PMN or cytoplasts were essentially as previously described (17) . Monolayers of adherent cytoplasts were formed by plating the cytoplasts and centrifuging the plates for 5 min at 150 g . The attachment index (AI) is the number of erythrocytes bound per 100 PMN . The phagocytic index (PI) represents the number of erythrocytes ingested by 100 PMN, counted after hypotonic lysis of uningested erythrocytes . Data are shown for representative experiments, since variation between preparations of PMN from different individuals precludes averaging of results .
Adhesion of PMN to Fibrinogen-coated Surfaces . Adhesion of PMN to fibrinogen-coated substrates was performed as described (7) . The number of adherent PMN within a x40 field were counted using a phase contrast microscope . All samples were run and counted in triplicate and averaged .
Isolation and Culture ofHuman Endothelial Cells . Human umbilical vein endothelial cells (EC) were isolated from fresh umbilical cords and cultured as previously described (4) . Primary EC cultures were subsequently seeded onto Terasaki plates that had been precoated with human fibronectin, and EC were cultured for 2-3 d before use in adhesion assays . EC monolayers were confluent by this time with typical cobblestone morphology, intact junctions (4), and expression of factor VIII-related antigen (19) .
Adhesion of PMN to EC. EC monolayers were fixed with 0 .25% glutaraldehyde in PBS at 4°C for 5 min, incubated with 50 mM glycine, 0 .15 M NaCl for 5 min, washed with PBS four to five times, and stored at 4°C . Adhesion of PDB-stimulated PMN to fixed EC monolayers was CD18-dependent, since the adhesion was blocked by pretreating the PMN with mAb IB4 (anti-CD18) (data not shown) . The details of the adhesion assay have been published elsewhere (4) .
Results and Discussion
NAP1/IL-8 Causes Increased Expression ofCDIIbICD18. The expression of CDllb/ CD18 on the surface of PMN as measured by flow cytometry increased in a concentration-dependent manner in response to NAP-1/1L-8 ( Fig . 1, stars) . The effect was apparent after exposure to 10 -9 M NAP-1/IL-8, which appears to correspond to the threshold concentration, and reached a maximum at 5 x 10 -8 M. The average increase in expression of CDllb/CD18 observed over several experiments was 2.9-fold, with a range of 2.1-4 .9-fold. The expression of CDllb/CD18 in response to 5 x 10 -8 M NAP-1/1L-8 was rapid, reaching a plateau by 15 min and remaining at that level for at least 90 min (Fig. 2 , open circles) . These results are consistent with the observation that NAP-1/IL-8 induces the rapid secretion of specific granules from PMN (20) , and specific granules serve as intracellular storage compartments for CDllb/CD18 (21) . Maximum upregulation of CDllb/CD18 was observed at concentrations of NAP-1/IL-8 that induce PMN chemotaxis, a rise in cytosolic free calcium, granule exocytosis (22, 23) , and transient actin polymerization (Detmers, P., (Figure 1, squares) .
Binding of EC3bi also increased an average of 5.3-fold in response to 5 x 10 -8 M fMLP (range 1.3-20.7-fold) (Fig . 1, open circles) . We previously reported that fmLP caused enhanced phagocytosis of EIgG and increased expression of CDllb/CD18 without a rise the binding activity of CDllb/CD18 (24) . These observations were made repeatedly with a single batch of fMLP that may have been chemically modified in such a way as to give a result that does not represent a normal response to formyl peptides . Our present observations of strong enhancement of the binding activity of CDllb/CD18 by fMLP were obtained with a different batch of fmLP and have been confirmed by similar results with a different formyl peptide, fNLLP (data not shown) .
Binding of EC3bi in response to NAP-1/IL-8 increased rapidly and appeared to reach a plateau by 15 min (Fig . 2, squares) . In some experiments we observed a biphasic response with a further increase in binding of EC3bi between 30 and 60 min.
Increased Expression of CD11b1CD18 is Not Necessaryfor Enhanced Binding ofEC3bi. We used PMN cytoplasts to determine if ligand binding was enhanced by NAP-1/IL-8 in the absence of newly expressed receptors. Flow cytometry with mAbs OKM10 (anti CD11b) and LeuM5 (anti CD11c) confirmed that neither of these two receptors increased on the cytoplast surface in response to NAP-1/IL-8 (data not shown) . However, NAP-1/IL-8 increased the binding of EC3bi to cytoplasts about threefold without changing the attachment of EIgG (Table I) . Thus, increased expression of CDllb/CD18 is not required to observe enhanced ligand-binding activity in response to NAP-1/IL-8, and the cytokine must therefore cause a qualitative change in CDllb/CD18 on the cell surface. One possible mechanism for increased receptor avidity in the absence of increased receptor expression is receptor aggregation. CD11b/CD18 moves into small aggregates on PMN in response to stimuli that enhance binding of EC3bi NAP-UIL-8 Enhances the Binding of LPS to PMN. CDllb/CD18 recognizes LPS through a binding site that is distinct from that which binds C3bi (25). 5 x 10-8 M NAP-1/IL-8 increased the binding oferythrocytes coated with the biosynthetic precursor of LPS, lipid IVa (EIVa), by an average of 16.1-fold (range 4-50-fold), and a large enhancement of EIVa binding was observed at concentrations as low as 10-9 M (Fig. 1, triangles) . NAP-1/IL-8 thus stimulated two different ligand-binding activities of CDllb/CD18 . This represents the first description of regulation of the LPS-binding activity of CDll/CD18, and this enhanced ability of PMN to recognize LPS could improve antimicrobial defense.
NAFUIL-8 Enhances Binding ofPMNto Fibrinogen. CDllb/CD18 recognizes a portion of the y-chain of fibrinogen containing the amino acid sequence Lys-Glu-AlaGly-AspVal (KQAGDV) (7). NAP-1/IL-8 at a concentration of 5 x 10 -8 M increased the binding of PMN to fibrinogen immobilized on plastic substrates by an average of 4.3-fold (range 1.6-9.4-fold), while it had no effect on the binding of PMN to control, HSA-coated substrates (Table II) . NAP-1/IL-8 may thus accelerate the interaction of PMN with fibrin deposits at sites of tissue injury.
NAP-UIL-8 Stimulates Binding of PMN to Endothelium. At a concentration of 5 x 10 -8 M NAP-1/IL-8, PMN adherence to unstimulated EC increased on average 1 .6-fold (Table II) . In contrast, PDB caused an average 3.4-fold increase in PMN adherence, indicating that NAP-1/IL-8 was a relatively mild stimulus of PMN-EC interaction . These results confirm those obtained by others (26) . Since EC may be stimulated to synthesize NAP-1/IL-8 (1), local secretion ofNAP-1/IL-8 may promote sufficient adhesion of PMN to EC in inflamed tissue to enable transmigration to occur. 
Summary
The cytokine NAP-1/IL-8 is produced by a variety of different cells in response to inflammatory stimuli and elicits several biological responses from PMN. Experiments presented here demonstrate that PMN exposed to NAP-1/IL-8 expressed increased amounts of CDllb/CD18, as well as CDllc/CD18 and CR1, on their cell surface, while expression of FcyRIII and HLA-A,B,C remained essentially unchanged. Increased CD11b/CD18 and CDllc/CD18 appears to correspond with the release of specific granules by NAP-1/IL-8 . NAP-1/IL-8 was also a potent stimulator of several of the binding activities of CDllb/CD18 . Ligation of EC3bi by CDllb/CD18 was rapidly enhanced by NAP-1/IL-8, but phagocytosis of the ligated particles was not induced by the agonist. In addition, enhanced binding of EC3bi was observed in the absence of an increase in receptor expression as shown with PMN cytoplasts . NAP-1/IL-8 promoted additional adhesive interactions between CDllb/CD18 and the biosynthetic precursor of LPS, lipid IVa, fibrinogen, and endothelial cells, suggesting that NAP-1/IL-8 may promote leukocyte adhesion in vivo that could lead to recruitment of PMN to sites of tissue inflammation .
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